NCT04978597View on ClinicalTrials.gov

Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

May 31, 2021

Primary Completion Date

January 11, 2023

Study Completion Date

January 26, 2024

Conditions
Parkinson
Interventions
DRUG

Opicapone 50 mg

Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI

DRUG

Placebo

Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI

Trial Locations (1)

2600

"Medical Centre Asklepii, OOD", Dupnitsa

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY